Humana recently announced that it will terminate its employer group line of business. This may make sense for Humana for two reasons: government programs currently provide a much higher ROI compared to commercial/employer business, and the company enjoys a strong Medicare Advantage (MA) market position (second only to United Healthcare Group) but has suffered from low market share in its commercial lines. By 2021, commercial lives contributed only 6% of the company’s revenue.
Humana By the Numbers
Expanding commercial volume inevitably requires stealing share from other insurers, while Medicare Advantage also offers the opportunity to convert fee-for-service Medicare lives to Medicare Advantage. However, by putting most of its eggs in one basket (Medicare Advantage), Humana increases its vulnerability to potential legislative changes to the program that may reduce the financial attractions. For example, CMS’ 2024 Advance Notice might reduce Medicare Advantage spending by an average of $540 per Medicare Advantage enrollee.
All our best...
-- HMP Market Access Insights Team
Bispecific antibodies have emerged with great promise, but adoption has been slower than expected. This was a key topic discussed by a panel of 5 experts at the October 2024 Association for Value-Based Cancer Care (AVBCC) conference.
Chris Van DenburgIn part 2 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore the operational realities of oncology practice economics.
Lee BlansettIn part 1 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore the current state of oncology practice economics.
Lee Blansett